The latent tuberculosis infection detection market size is estimated to be USD 1,785.2 million in 2022 and is expected to witness a CAGR of 6.17% during the forecast period 2023-2033. Escalating risk of contracting active tuberculosis and growing public awareness of the importance of early tuberculosis infection diagnosis are some of the factors contributing to the market growth. Furthermore, rising approval of technologically developed tests for latent tuberculosis infection detection and increasing immigration to developed nations including Canada, the U.K., the U.S., and other European countries are other factors supporting the market growth. However, strict governmental regulations and lack of knowledge in new countries is expected to hinder the growth.

Rising approval of technologically developed tests for latent tuberculosis infection detection is expected to propel the market growth during the projected period. For instance, the QuantiFERON-TB gold plus assay for use on LIAISON XS, a DiaSorin automated platform, was approved by the U.S. FDA in November 2021. The United States has more widespread access to latent tuberculosis testing due to this approval. Additionally, bioMerieux declared a CE certification for their IGRA test on VIDAS for the diagnosis of latent TB infection in March 2021.

Increasing immigration to developed nations including Canada, the U.K., the U.S., and other European countries is predicted to fuel the market growth during the forecast period. By 2024, the Canadian government projects that there will be approximately 1.3 million new professionals who have immigrated to the nation. Similarly, the U.K. government reports that up to June 2022, 331,233 work visas had been issued to individuals from all around the world. For immigrants applying for visas from areas where tuberculosis is common, the U.K. government has made TB tests compulsory. As a result, tuberculosis screening tests are needed in areas with high rates of immigration from countries with a high frequency of LTBI.

Segmentation

By Test Type

The market is categorized into interferon gamma released assay, tuberculin skin test. In 2022, the tuberculin skin test segment accounted for the highest revenue share due to the growing market penetration of the tuberculin skin test (TST) for the detection of LTBI, particularly in areas with a high tuberculosis prevalence rate, such Asia Pacific and Africa. The increased demand for these tests is also being fueled by the cost-effectiveness of TST and the increase in public awareness of tuberculosis infection detection. Latent TB disease and TB are diagnosed by TST testing. The IGRA segment is anticipated to experience a large revenue share over the projected period. The use of IGRA testing for LTBI detection is growing as a result of factors including their advantages over conventional tests, accuracy, and their high sensitivity. Additionally, segment growth is estimated to be fueled in the upcoming years by IGRA tests’ regional expansion. For instance, the T-SPOT TB Test and the QuantiFERON TB Test are two IGRA tests that have received approval from the U.S. FDA. In the US, these tests are readily accessible for detecting latent tuberculosis infection.

By Application

The market is categorized into PLHIV, household contacts with pulmonary TB, and others. In the global market, the PLHIV segment accounted for the largest revenue share in 2022 owing to rise in risk of acquiring active tuberculosis in persons living with HIV and the significant requirement to treat the condition for HIV patients to live longer. The main cause of death in PLHIV patients, according to the WHO, is tuberculosis. In addition, the WHO’s global TB report states that PLHIV are 18 times more likely than non-PLHIV individuals to have active tb disease. Household contacts with pulmonary TB also represented the second-largest market share and are anticipated to expand at a profitable rate during the projected period due to the fact that TB can be passed from person to person through the air, it is a contagious disease. The high prevalence of pulmonary TB and growing public awareness of TB infection testing regulate the segment’s expansion.

By End User

The market is segmented into academic & research institutions, diagnostic laboratories, and hospitals/clinics. In 2022, the diagnostic laboratories segment accounted for the largest revenue share owing to increase in the burden of infectious diseases and the surge in widespread usage of technologically advanced products in laboratories for precise results. Additionally, it’s expected that the ability to complete many treatments rapidly would boost segment growth. The high rate of adoption of more recent blood tests in diagnostic labs for the screening or detection of LTBIs is also contributing to the sector share growth. The academic and research institutions segment is anticipated to increase at a profitable rate during the projection period. Over the projection period, segment growth is anticipated to be fueled by rising awareness of personalised treatment strategies and medical technology improvements in the field of TB treatment.

Regional Markets

In 2022, Asia Pacific region accounted for the highest revenue in the latent tuberculosis infection detection market and is expected to maintain its dominance during the forecast period. This is attributed to targeted population, high prevalence of latent TB infection, and the rise in demand for affordable diagnostic. Around 31% of people in South East Asia and 28% of people in the Western Pacific have LTBI. Additionally, it is anticipated that increased emphasis on R&D activities associated to the creation of innovative diagnostic solutions will accelerate market expansion in the Asia Pacific region. The regions of North America and Europe held a significant percentage of the LTBI detection market. This is credited to supportive government programmes for TB testing and diagnosis, rising awareness of early infection detection, and continued funding for efforts to fight TB infection in these areas. For instance, the United States is the largest funder of global TB control activities, having allocated USD 332 million to reducing the threat of tuberculosis in 2021. Furthermore, it is projected that the presence of a large number of major companies and the many strategic initiatives they have undertaken will help the region’s expansion.

Competitor Insights

Some of the key players operating in the latent tuberculosis infection detection market are Serum Institute of India Pvt. Ltd, Abbott, F. Hoffmann-La Roche Ltd, Lionex GmbH, Oxford Immunotec USA, Inc, Becton, Dickinson, and Company, bioMerieux, and Sanofi.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, QIAGEN got approval for the QuantiFERON TB test in China in February 2022. In the upcoming years, this is certainly going to increase the company’s market share.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including test type, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Latent Tuberculosis Infection Detection Market Report 2022 – 2033

Test Type (Revenue, USD Million), 2022 – 2033

• Interferon Gamma Released Assay
• Tuberculin Skin Test

Application (Revenue, USD Million), 2022 – 2033

• PLHIV
• Household Contacts with Pulmonary TB
• Others

End user (Revenue, USD Million), 2022 – 2033

• Academic & Research Institutions
• Diagnostic Laboratories
• Hospitals/Clinics

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA